A5011690431- PI3K/AKT/mTOR signaling in cancer
- Hepatocellular Carcinoma Treatment and Prognosis
- Nanoparticle-Based Drug Delivery
- HER2/EGFR in Cancer Research
- Cancer Mechanisms and Therapy
- Monoclonal and Polyclonal Antibodies Research
- Melanoma and MAPK Pathways
- Liver physiology and pathology
- Cytokine Signaling Pathways and Interactions
- HIV/AIDS drug development and treatment
- Lung Cancer Treatments and Mutations
- Cancer, Lipids, and Metabolism
- Ubiquitin and proteasome pathways
- Pneumocystis jirovecii pneumonia detection and treatment
- Autophagy in Disease and Therapy
- Wnt/β-catenin signaling in development and cancer
- Synthesis and biological activity
- HIV Research and Treatment
- Cancer therapeutics and mechanisms
- Cancer, Hypoxia, and Metabolism
- Chemical Synthesis and Analysis
- Click Chemistry and Applications
- Multiple Myeloma Research and Treatments
- PARP inhibition in cancer therapy
- Advanced Glycation End Products research
Anhui University of Science and Technology
2018-2024
Anhui University
2020
Kumamoto University
2013
Peking University
2007
University of Southern California
2003
Sorafenib (SFB) has improved the treatment of hepatocellular carcinoma (HCC) and fewer severe side effects than other agents used for that purpose. However, due to a lack tumor-specific targeting, concentration drug in tumor tissue cannot be permanently maintained at level inhibits growth. To overcome this problem, we developed novel SFB-loaded polymer nanoparticle (NP). The NP (a TPGS-b-PCL copolymer was synthesized from ε-caprolactone d-α-tocopheryl polyethylene glycol 1000 succinate...
Background: Sorafenib, an oral multi-kinase inhibitor of rapidly accelerated fibrosarcoma; vascular endothelial growth factor receptor-2/3, platelet-derived receptor, c-Kit, and Flt-3 signaling, is approved for treatment advanced hepatocellular carcinoma (HCC). However, the benefit sorafenib often diminished because acquired resistance through reactivation ERK signaling in sorafenib-resistant HCC cells. In this work, we investigated whether adding LY3214996, a selective ERK1/2 inhibitor, to...
Liver cancer remains one of the leading causes deaths worldwide. The therapeutic effect oxaliplatin on liver is often limited by acquired resistance cells. Abnormal activation PI3K/AKT pathway plays an important role in oxaliplatin. present study investigated effects PI3K inhibitor LY‑294002 and AKT MK2206 chemosensitivity oxaliplatin‑resistant cells molecular mechanism involved. An cell line HepG2<sup>R</sup> was developed. MTT assay, clone formation experiments, flow cytometry Annexin...
Novel 6-substituted-4-cycloalkyloxy-pyridin-2(1H)-ones were synthesized as non-nucleoside reverse transcriptase inhibitors (NNRTIs), and their biological activity was evaluated. Most of the compounds, especially 26 22, bearing a 3-isopropyl 3-iodine group, respectively, exhibited highly potent against wild-type HIV-1 strains those resistant to (RTIs). The diastereoisomers 26-trans 26-cis separately confirmed with HPLC NOESY spectra. isomers had an about 400-fold more than that 26-cis. pair...
Sorafenib has shown modest therapeutic effectiveness against hepatocellular carcinoma (HCC), but more effective therapies are needed. The objective of this research was to test the feasibility using sorafenib-loaded polymer nanoparticles (NP-SFB) enhance tumor. Biodegradable d-α-tocopherol polyethylene glycol 1000 succinatepolycaprolactone (TPGS-b-PCL) were prepared by a modified nanoprecipitation method and tested for anti-tumor effect in HepG2 hepatoma cells HCC xenograft mouse model....
Background: The combination of BEZ235 with sorafenib (SFB) enhances anti-hepatocellular carcinoma (HCC) efficacy the two agents. However, pharmacokinetic profiles in vivo and different endocytosis abilities these drugs hinder their therapeutic application.Research design methods: In this work, we developed d-α-tocopheryl polyethylene glycol 1000 succinate - polycaprolactone polymer nanoparticles (NPs) for co-delivery SFB (SFB/BEZ235-NPs). Explored anti-proliferative pro-apoptotic effects...
Epithelial mesenchymal transition (EMT) and inflammation have been identified as carcinogenic agents. This study aims to investigate whether inhibition of trichloroethylene (TCE) associated hepatocellular carcinoma (HCC) by curcumin is with EMT.In the current study, TCE sub-chronic cell model was induced in vitro, effects on proliferation, migration, invasion, expression functional proteins were verified Western blot, MTT, clone formation, wound healing, Transwell. The detoxification effect...
Delivery of tumor-specific inhibitors is a challenge in cancer treatment. Antibody-modified nanoparticles can deliver their loaded drugs to tumor cells that overexpress specific tumor-associated antigens. Here, we constructed sorafenib-loaded polyethylene glycol-b-PLGA polymer modified with antibody hGC33 glypican-3 (GPC3 +), membrane protein overexpressed hepatocellular carcinoma. We found hGC33-modified NPs (hGC33-SFB-NP) targeted GPC3+ carcinoma (HCC) by specifically binding GPC3 on the...
Acquired resistance of hepatocellular carcinoma (HCC) to sorafenib (SFB) is the main reason for failure SFB treatment cancer. Abnormal activation PI3K/AKT/mTOR pathway important in acquired SFB. Therefore, we investigated whether BEZ235 (BEZ) could reverse by targeting PI3K/mTOR pathway. A sorafenib-resistant HCC cell line Huh7R was established. MTT assay, clone formation flow cytometry, and immunofluorescence were used analyze effects alone or combined with on proliferation, cycle,...
Radiation is an important therapeutic strategy for hepatocellular (HCC). In this study, we evaluated the role of dual PI3K/mTOR inhibitor, PKI-587, on radiosensitization HCC and its possible mechanism. MTT, colony formation, flow cytometry, immunofluorescence were used to analyze proliferation, cell cycle, formation residual γ-H2AX foci, apoptosis cells. A SK-Hep1 xenograft model was assess effects PKI-587 in combination with ionizing radiation vivo. The activation levels PI3K/AKT/mTOR DNA...
Adenomatous polyposis coli ( APC ) is the most commonly mutated gene in colon cancer and can cause familial adenomatous (FAP). Hypermethylation of promoter also promote development breast cancer, indicating that not limited to association with colorectal neoplasms. However, no pan-cancer analysis has been conducted. We studied location structure expression potential role a variety tumors by using The Cancer Genome Atlas Gene Expression Omnibus databases online bioinformatics tools. located...
Abstract Polymer materials encapsulating drugs have broad prospects for drug delivery. We evaluated the effectiveness of polyethylene glycol-poly (lactic-co-glycolic acid) (PLGA-PEG) encapsulation and release characteristics PI3K/mTOR inhibitor NVP-BEZ235 (BEZ235). proposed a strategy targeting radiosensitization liver cancer cells. The biocompatibility, cell interaction, internalization Glypican-3 (GPC3) antibody-modified, BEZ235-loaded PLGA-PEG nanoparticles (NP-BEZ235-Ab) in hepatoma...
We, the authors, Editors and Publisher of journal Artificial Cells, Nanomedicine, Biotechnology, have retracted following article:Ling Rong, Shuping Zhou, Xinkuang Liu, Amin Li, Tao Jing, Xueke Yinci Zhang, Shiyu Cai & Xiaolong Tang (2018) Trastuzumab-modified DM1-loaded nanoparticles for HER2+ breast cancer treatment: an in vitro vivo study. 46:8, 1708–1718, DOI: 10.1080/21691401.2017.1391821Since publication, authors noticed errors Figures 7 b 5c, which directly impacts reported results...
The mTOR signal pathway is often highly activated in B-cell non-Hodgkin's lymphoma (NHL) and promotes cancer progression chemo-resistance. Therefore, the pathways of are an important target for drug development this disease. In current study, we developed a rituximab (anti-CD20)-modified inhibitor, AZD-2014, loaded into nanoparticles (Ab-NPs-AZD-2014) trial its anti-NHL effect. cultured NHL cell line, Ab-NPs-AZD-2014 inhibited growth, induced apoptosis, blocked activation mTORC1 mTORC2 Raji...
Abstract 1‐(Alkyl)‐5‐dimethylamino‐6‐phenethyl uracils (1) and (2) are analogs of MKC‐442, which is a very potent inhibitor HIV‐1 reverse transcriptase. The target compound 1 was synthesized by the first approach, from corresponding 1,3‐dibenzyl‐5‐(dimethylamino)‐6‐phenethylpyrimidine‐2,4(1H,3H)‐dione (7), in four steps 6‐methyluracil (3) nitration, benzylation, reduction, methylation amino group. Compound 7 then debenzylated to give complete deprotected 8 with low yield. To improve yield,...
Abstract Background: Mutant KRAS is an important driver of tumor and has remained undruggable target for decades. Despite the success mutant-specific KRASG12C inhibitors, there limited therapeutics most KRAS-mutated patients (e.g., KRASG12D, KRASG12V KRASG13D). Developing KRASMulti inhibitor targeting a broad range KRAS-driven cancers another promising strategy. Methods: The Induced Allosteric Drug Discovery Platform (IADDP) integrating medicinal chemistry, biophysical studies computational...
Abstract Background: As a key tumor suppressor, p53 precisely regulates cellular events such as cell cycle arrest, apoptosis, senescence, and DNA repair under physiological conditions. In 50-60% of human cancers, TP53 gene is mutated. The Y220C hotspot loss-of-function mutation occurring in around 1% solid tumors. Application p53-Y220C reactivator for restoration function represents promising treatment strategy patients with this mutation. Methods: Induced Allosteric Drug Discovery Platform...
Pre-frailty is common in patients undergoing maintenance hemodialysis (MHD). Without proper management, it can quickly worsen and progress into frailty, leading to various adverse clinical outcomes. Therefore, timely interventions for pre-frail MHD are crucial. However, the response of such currently unclear. This study evaluated effect a multicomponent intervention on changes pre-frailty status, risk factors quality life, outcomes MHD.